(Till\u00e4gg: f\u00f6rs\u00e4ljning f\u00f6r l\u00e4kemedlen Mounjaro och Zepbound)<\/p>\n
STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Det amerikanska l\u00e4kemedelsbolaget Eli Lilly redovisar ett justerat resultat per aktie p\u00e5 8:55 dollar f\u00f6r det f\u00f6rsta kvartalet 2026.<\/p>\n
Analytikernas f\u00f6rv\u00e4ntningar var ett resultat p\u00e5 6:79 dollar per aktie, enligt en snittprognos fr\u00e5n S&P Global Market Intelligence.<\/p>\n
F\u00f6rs\u00e4ljningen var 19,8 miljarder dollar. V\u00e4ntat var en f\u00f6rs\u00e4ljning p\u00e5 17,8 miljarder dollar.<\/p>\n
Diabetesl\u00e4kemedlet Mounjaro, som konkurrerar med Novo Nordisks Ozempic, s\u00e5lde f\u00f6r 8,7 miljarder dollar i kvartalet, upp 125 procent j\u00e4mf\u00f6rt med motsvarande kvartal f\u00f6r ett \u00e5r sedan.<\/p>\n
Fetmal\u00e4kemedlet Zepbound \u00f6kade f\u00f6rs\u00e4ljningen med 80 procent till 4,2 miljarder dollar. Detta l\u00e4kemedel konkurrerar med Novo Nordisks Wegovy.<\/p>\n
B\u00f6rsredaktionen Nyhetsbyr\u00e5n Direkt<\/p>\n
+46 8 5191 7911<\/p>\n
borsdesken.direkt@direkt.se<\/p>\n","protected":false},"excerpt":{"rendered":"(Till\u00e4gg: f\u00f6rs\u00e4ljning f\u00f6r l\u00e4kemedlen Mounjaro och Zepbound) STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Det amerikanska l\u00e4kemedelsbolaget Eli Lilly redovisar ett justerat…\n","protected":false},"author":2,"featured_media":218265,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,6631,6456,6457,34,31,33,32,30],"class_list":["post-233058","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-eli-lilly","tag-novo-nordisk-adr","tag-novo-nordisk-b","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116493885459566231","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/233058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=233058"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/233058\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/218265"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=233058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=233058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=233058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}